Using bacteriophages to treat Shigella infections
Bacteriophage-based approach for managing Shigella infections
This study is looking at a new way to treat Shigella infections using special viruses that can kill the harmful bacteria, which could be a great option for kids under five who often get these infections, especially since antibiotics aren't always working anymore.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Intralytix, INC. NIH-funded |
| Lab location | 1 site (Columbia, UNITED STATES) |
| Project ID | NIH-10830381 on NIH RePORTER |
What this research studies
This research focuses on developing a novel treatment for Shigella infections using bacteriophages, which are viruses that specifically target and kill bacteria. The approach aims to provide an alternative to traditional antibiotics, especially in light of rising antibiotic resistance. By utilizing bacteriophages, the research seeks to create an effective and affordable treatment option that can be distributed in resource-limited settings, particularly benefiting children under five who are most affected by these infections. The methodology involves isolating and characterizing specific bacteriophages that can effectively combat Shigella strains.
Who could benefit from this research
Good fit: Ideal candidates for this research are children under the age of five who are suffering from Shigella infections.
Not a fit: Patients with Shigella infections who are older than five years or those with other underlying health conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new, effective treatment for Shigella infections, significantly reducing morbidity and mortality rates in affected populations.
How similar studies have performed: Other research has shown promise in using bacteriophages to treat bacterial infections, indicating that this approach could be a viable alternative to traditional antibiotics.
Where this research is happening
Columbia, UNITED STATES
- Intralytix, INC. — Columbia, United States (Active)
Researchers
- Principal investigator: Sulakvelidze, Alexander — Intralytix, INC.
- Study coordinator: Sulakvelidze, Alexander
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.